| Literature DB >> 30618112 |
Jung Hye Kim1, Kahui Park1, Sang Bae Lee1, Shinae Kang1,2, Jong Suk Park1,2, Chul Woo Ahn1,2, Ji Sun Nam1,2.
Abstract
AIMS/Entities:
Keywords: Hyperglycemia; Natural killer cell activity; Type 2 diabetes mellitus
Mesh:
Substances:
Year: 2019 PMID: 30618112 PMCID: PMC6717814 DOI: 10.1111/jdi.13002
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Baseline characteristics of study participants
| Type 2 DM | Non‐DM |
| ||
|---|---|---|---|---|
| Prediabetes (IGT or IFG) | NGT | |||
|
| 21 | 15 | 13 | |
| Sex | ||||
| Men ( | 8 | 5 | 4 | |
| Women ( | 13 | 10 | 9 | |
| Age (years) | 60.71 ± 6.99 | 58.80 ± 10.27 | 53.69 ± 13.76 | 0.153 |
| Current smoker (%) | 38.1 | 40 | 15.4 | 0.307 |
| SBP (mmHg) | 128.00 ± 14.84 | 130.53 ± 17.79 | 118.62 ± 14.00 | 0.104 |
| DBP (mmHg) | 76.33 ± 9.79 | 84.27 ± 14.42 | 79.00 ± 13.47 | 0.307 |
| BMI (kg/m2) | 23.55 ± 2.75 | 24.71 ± 2.35 | 23.10 ± 3.54 | 0.304 |
| FPG (mmol/L) | 10.55 ± 3.47 | 5.82 ± 0.53 | 5.13 ± 0.31 | <0.001 |
| HbA1c (%) | 8.86 ± 1.61 | 5.85 ± 0.36 | 5.35 ± 0.35 | <0.001 |
| 2hPG (mmol/L) | 15.54 ± 4.75 | 6.94 ± 1.48 | 5.85 ± 0.69 | <0.001 |
| Total cholesterol (mmol/L) | 5.13 ± 0.96 | 4.90 ± 0.93 | 4.86 ± 1.15 | 0.699 |
| Triglyceride (mmol/L) | 2.08 ± 1.21 | 1.72 ± 0.80 | 1.43 ± 0.79 | 0.182 |
| HDL cholesterol (mmol/L) | 1.31 ± 0.33 | 1.36 ± 0.26 | 1.40 ± 0.35 | 0.708 |
| LDL cholesterol (mmol/L) | 3.39 ± 0.75 | 3.25 ± 0.92 | 3.26 ± 1.03 | 0.865 |
| Fasting C‐peptide (nmol/L) | 0.59 ± 0.25 | 0.75 ± 0.23 | 1.05 ± 0.43 | 0.007 |
| Fasting insulin (pmol/L) | 46.53 ± 37.78 | 62.30 ± 31.67 | 118.76 ± 129.59 | <0.001 |
| HOMA‐B | 34.40 ± 17.09 | 100.33 ± 22.56 | 152.15 ± 35.38 | <0.001 |
| HOMA‐IR | 1.89 ± 1.45 | 1.73 ± 0.52 | 2.21 ± 0.94 | 0.224 |
| NK cell activity | 768.01 ± 650.35 | 2396.08 ± 653.76 | 2435.31 ± 633.22 | <0.001 |
Data are presented as the mean (standard deviation). The P‐value represents the analysis of variance P for the baseline measures among the groups. † P < 0.05 between normal glucose tolerance (NGT) and type 2 diabetes mellitus (DM), ‡ P < 0.05 between prediabetes (impaired glucose tolerance [IGT] and impaired fasting glucose [IFG]) and type 2 DM, § P < 0.05 between non‐DM (NGT and prediabetes) and type 2 DM, ¶ P < 0.05 between NGT and prediabetes (IGT and IFG). 2hPG, 2‐h postload glucose; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; HOMA‐B, homeostatic model assessment of β‐cell function; HOMA‐IR, homeostatic model assessment of insulin resistance; LDL, low‐density lipoprotein; NK, natural killer; SBP, systolic blood pressure.
Correlation analysis between biochemical parameters including natural killer cell activity after adjusting for age, sex, blood pressure and smoking status
| NK cell activity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Type 2 DM | Prediabetes | NGT | All participants | |||||
|
|
|
|
|
|
|
|
| |
| BMI | 0.193 | 0.459 | 0.409 | 0.240 | −0.040 | 0.925 | 0.162 | 0.294 |
| FPG | −0.705 | <0.001 | −0.208 | 0.565 | −0.395 | 0.333 | −0.745 | <0.001 |
| HbA1c | −0.790 | <0.001 | −0.470 | 0.170 | −0.751 | 0.032 | −0.827 | <0.001 |
| 2hPG | −0.795 | <0.001 | 0.268 | 0.453 | −0.608 | 0.109 | −0.778 | <0.001 |
| Total cholesterol | −0.264 | 0.306 | 0.032 | 0.929 | −0.407 | 0.317 | −0.245 | 0.109 |
| Triglyceride | −0.003 | 0.990 | 0.624 | 0.054 | −0.419 | 0.302 | −0.183 | 0.235 |
| HDL cholesterol | −0.131 | 0.616 | −0.427 | 0.219 | 0.332 | 0.422 | 0.036 | 0.818 |
| LDL cholesterol | −0.267 | 0.300 | 0.188 | 0.604 | −0.448 | 0.265 | −0.186 | 0.228 |
| Fasting C‐peptide | −0.350 | 0.169 | 0.179 | 0.621 | 0.196 | 0.642 | 0.219 | 0.153 |
| Fasting insulin | −0.297 | 0.247 | −0.009 | 0.980 | 0.749 | 0.032 | 0.302 | 0.046 |
| HOMA‐B | 0.649 | 0.005 | 0.387 | 0.269 | 0.244 | 0.560 | 0.738 | <0.001 |
| HOMA‐IR | −0.489 | 0.046 | 0.187 | 0.606 | 0.090 | 0.833 | −0.212 | 0.166 |
Data are presented as the mean (standard deviation). 2hPG, 2‐h postload glucose; BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; HOMA‐B, homeostatic model assessment of β‐cell function; HOMA‐IR, homeostatic model assessment of insulin resistance; IR, insulin resistance; LDL, low‐density lipoprotein; NK, natural killer; NGT, normal glucose tolerance.
Multiple stepwise regression analysis between natural killer cell activity and biochemical parameters in type 2 diabetes mellitus and all participants
| B (95% CI) | β |
|
| |
|---|---|---|---|---|
| NK cell activity in type 2 DM | ||||
| FPG | 4.499 [0.894, 8.104] | 0.432 | 0.459 | 0.233 |
| HbA1c | −280.787 [−347.053, −214.521] | −0.697 | 0.459 | <0.001 |
| 2hPG | −2.381 [−4.724, −0.038] | −0.313 | 0.459 | 0.327 |
| HOMA‐B | 14.096 [4.745, 23.447] | 0.370 | 0.459 | 0.154 |
| NK cell activity in all participants | ||||
| FPG | 4.702 [0.208, 9.196] | 0.277 | 0.713 | 0.302 |
| HbA1c | −317.849 [−384.927, −250.771] | −0.599 | 0.713 | <0.001 |
| 2hPG | −2.345 [−4.602, −0.088] | −0.228 | 0.713 | 0.305 |
| Fasting C‐peptide | −96.849 [−249.246, 55.548] | −0.098 | 0.713 | 0.529 |
| Fasting insulin | 5.527 [−3.117, 14.171] | 0.059 | 0.713 | 0.526 |
| HOMA‐B | 5.596 [3.199, 7.993] | 0.295 | 0.713 | 0.024 |
Data are presented as the mean. 2hPG, 2‐h postload glucose; CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HOMA‐B, homeostatic model assessment of β‐cell function; NK, natural killer.